Circle Pharma announced publication of research in the Journal of Medicinal Chemistry highlighting optimization of oral cyclin A/B RxL inhibitors.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.
[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
A 'pocket' on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Cell division is key for life. Every organism -- from the smallest yeast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results